Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 120 articles: HTML format

Single Articles

October 2024
1. NIERENGARTEN MB
   Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer.
   Cancer. 2024;130:3399.
   PubMed    
   
   
   September 2024
2. ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al
   Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
   Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568.
   PubMed     Abstract available
   
   
   
3. KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al
   Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
   Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498.
   PubMed     Abstract available
   
   
   
4. 
   Addition of apalutamide to ADT after radical prostatectomy offers encouraging results.
   Cancer. 2024;130:2896.
   PubMed    
   
   
   
5. NIERENGARTEN MB
   Optimal timing of radiotherapy after radical prostatectomy points to salvage radiotherapy for PSA failure.
   Cancer. 2024;130:2895.
   PubMed    
   
   
   August 2024
6. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
   Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
   Cancer. 2024;130:2770-2781.
   PubMed     Abstract available
   
   
   July 2024
7. MORGANS AK
   Optimizing assessments of quality of life in contemporary prostate cancer clinical trials.
   Cancer. 2024 Jul 27. doi: 10.1002/cncr.35485.
   PubMed    
   
   
   
8. LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al
   Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
   Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472.
   PubMed     Abstract available
   
   
   
9. MEAGHER M, Morgan K, Deshler L, Riviere P, et al
   Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
   Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469.
   PubMed     Abstract available
   
   
   
10. SANYAL C, Ragavan MV
    Beyond the PSA: The hidden costs of screening in prostate cancer.
    Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474.
    PubMed    
    
    
    
11. NIERENGARTEN MB
    Novel hormone is safe and effective in men receiving radiotherapy for prostate cancer.
    Cancer. 2024;130:2408.
    PubMed    
    
    
    
12. SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al
    Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
    Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392.
    PubMed     Abstract available
    
    
    
13. GONG J, Janes JL, Trustram Eve C, Stock S, et al
    Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
    Cancer. 2024 Jul 1. doi: 10.1002/cncr.35466.
    PubMed     Abstract available
    
    
    June 2024
14. MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al
    Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438.
    PubMed     Abstract available
    
    
    
15. BASARIA S, Taplin ME, McDonnell M, Simonson DC, et al
    Insulin resistance during androgen deprivation therapy in men with prostate cancer.
    Cancer. 2024 Jun 16. doi: 10.1002/cncr.35443.
    PubMed     Abstract available
    
    
    
16. PAGADALA MS, Lui A, Lynch J, Karunamuni R, et al
    Healthy lifestyle and prostate cancer risk in the Million Veteran Program.
    Cancer. 2024 Jun 12. doi: 10.1002/cncr.35434.
    PubMed     Abstract available
    
    
    
17. LABBAN M, Stone BV, Steele GL, Salinas KE, et al
    A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366.
    PubMed     Abstract available
    
    
    May 2024
18. TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al
    Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
    PubMed     Abstract available
    
    
    April 2024
19. BENADADA F, Saad F, Delouya G, Taussky D, et al
    Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries.
    Cancer. 2024;130:1019-1024.
    PubMed     Abstract available
    
    
    March 2024
20. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
    A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
    PubMed     Abstract available
    
    
    
21. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
    High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
    Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
    PubMed     Abstract available
    
    
    
22. LIM FAT G, Alibhai S
    Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
    PubMed    
    
    
    
23. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    PubMed     Abstract available
    
    
    February 2024
24. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    PubMed     Abstract available
    
    
    
25. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    PubMed     Abstract available
    
    
    
26. WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al
    The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241.
    PubMed     Abstract available
    
    
    
27. LOEB S, Hua Q, Bauer SR, Kenfield SA, et al
    Plant-based diet associated with better quality of life in prostate cancer survivors.
    Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172.
    PubMed     Abstract available
    
    
    
28. HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al
    Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221.
    PubMed     Abstract available
    
    
    
29. DORFF TB, Bryce AH
    Challenges in clinical trials for high-risk but curable prostate cancer.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245.
    PubMed    
    
    
    
30. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    PubMed     Abstract available
    
    
    January 2024
31. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed     Abstract available
    
    
    
32. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    PubMed     Abstract available
    
    
    
33. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    PubMed     Abstract available
    
    
    
34. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    PubMed     Abstract available
    
    
    December 2023
35. FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al
    Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168.
    PubMed     Abstract available
    
    
    
36. 
    FDA approves new combined treatment for advanced prostate cancer.
    Cancer. 2023;129:3841-3842.
    PubMed    
    
    
    
37. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Reply to "Contextualizing racial associations in prostate cancer to expose structural causes".
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167.
    PubMed    
    
    
    
38. ROLLIN FG, Olsen E, George M
    Contextualizing racial associations in prostate cancer to expose structural causes.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157.
    PubMed    
    
    
    
39. GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al
    The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Cancer. 2023;129:3790-3796.
    PubMed     Abstract available
    
    
    November 2023
40. YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al
    Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
    Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133.
    PubMed     Abstract available
    
    
    
41. NIERENGARTEN MB
    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.
    PubMed    
    
    
    
42. BRAWLEY OW, Ramalingam R
    The enigma of race and prostate cancer.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032.
    PubMed    
    
    
    
43. LEE KM, Bryant AK, Lynch JA, Robison B, et al
    Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979.
    PubMed     Abstract available
    
    
    October 2023
44. NIERENGARTEN MB
    Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities.
    Cancer. 2023;129:3192.
    PubMed    
    
    
    
45. LEEMAN JE, Shin KY, Chen YH, Mak RH, et al
    Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Cancer. 2023;129:3044-3052.
    PubMed     Abstract available
    
    
    September 2023
46. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Racial differences in serum chemokines in prostate cancer patients.
    Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012.
    PubMed     Abstract available
    
    
    
47. JACKSON-SPENCE F, Young M, Sweeney C, Powles T, et al
    Top advances of the year: Genitourinary cancer.
    Cancer. 2023;129:2603-2609.
    PubMed     Abstract available
    
    
    August 2023
48. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
    Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
    Cancer. 2023;129:2522-2531.
    PubMed     Abstract available
    
    
    
49. NIERENGARTEN MB
    Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression.
    Cancer. 2023;129:2277.
    PubMed    
    
    
    
50. NIERENGARTEN MB
    Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
    Cancer. 2023;129:2278.
    PubMed    
    
    
    July 2023
51. JOHNSTONE PAS
    Magnetic resonance guidance is enough for prostate cancer: save adaptation for the patients it will really help.
    Cancer. 2023 Jul 24. doi: 10.1002/cncr.34835.
    PubMed    
    
    
    
52. KICIAK A, Clark W, Uhlich M, Letendre A, et al
    Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.
    Cancer. 2023 Jul 10. doi: 10.1002/cncr.34812.
    PubMed     Abstract available
    
    
    June 2023
53. HERR DJ, Elliott DA, Duchesne G, Stensland KD, et al
    Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.
    Cancer. 2023 Jun 30. doi: 10.1002/cncr.34916.
    PubMed     Abstract available
    
    
    
54. HORNY M, Yabroff KR, Filson CP, Zheng Z, et al
    The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
    Cancer. 2023 Jun 17. doi: 10.1002/cncr.34905.
    PubMed     Abstract available
    
    
    May 2023
55. MURPHY AB
    An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34886.
    PubMed     Abstract available
    
    
    
56. RENCSOK EM, Stopsack KH, Slopen N, Odedina FT, et al
    Experience with the US health care system for Black and White patients with advanced prostate cancer.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34885.
    PubMed     Abstract available
    
    
    
57. NIERENGARTEN MB
    MRI-guided radiotherapy results in fewer toxicities for localized prostate cancer.
    Cancer. 2023;129:1303-1304.
    PubMed    
    
    
    April 2023
58. WEINER AB, Liu Y, Hakansson A, Zhao X, et al
    A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
    Cancer. 2023 Apr 14. doi: 10.1002/cncr.34790.
    PubMed     Abstract available
    
    
    March 2023
59. MCDONALD AM, DeMora L, Yang ES, Hoyle JM, et al
    Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
    Cancer. 2023;129:685-696.
    PubMed     Abstract available
    
    
    February 2023
60. NYAME YA, Holt SK, Etzioni RD, Gore JL, et al
    Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
    Cancer. 2023 Feb 13. doi: 10.1002/cncr.34681.
    PubMed     Abstract available
    
    
    
61. CENAT JM, Dromer E, Darius WP, Dalexis RD, et al
    Incidence, factors, and disparities related to cancer among Black individuals in Canada: A scoping review.
    Cancer. 2023;129:335-355.
    PubMed     Abstract available
    
    
    January 2023
62. 
    Gut microbiota differs significantly between men with and without prostate cancer.
    Cancer. 2023;129:169-170.
    PubMed    
    
    
    
63. FANG AM, Shumaker LA, Rais-Bahrami S
    Reply to "Micro-ultrasound may significantly reduce the proportion of unnecessary prostate biopsies in patients with PI-RADS 3 lesions".
    Cancer. 2023;129:322.
    PubMed    
    
    
    
64. AVOLIO PP, Lazzeri M, Buffi NM, Lughezzani G, et al
    Micro-ultrasound may significantly reduce the proportion of unnecessary prostate biopsies in patients with PI-RADS 3 lesions.
    Cancer. 2023;129:320-321.
    PubMed    
    
    
    
65. 
    Metastasis-directed therapy plus hormone therapy improves progression-free survival for advanced prostate cancer.
    Cancer. 2023;129:9.
    PubMed    
    
    
    December 2022
66. FECTEAU R, Lee WR
    The importance of body composition in patients with prostate cancer receiving radiotherapy.
    Cancer. 2022 Dec 29. doi: 10.1002/cncr.34594.
    PubMed    
    
    
    November 2022
67. 
    MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis.
    Cancer. 2022;128:3906.
    PubMed    
    
    
    
68. RIVIERE P, Kalavacherla S, Banegas MP, Javier-Desloges J, et al
    Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34530.
    PubMed     Abstract available
    
    
    
69. TAN WP, Kotamarti S, Chen E, Mahle R, et al
    Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Cancer. 2022;128:3824-3830.
    PubMed     Abstract available
    
    
    October 2022
70. 
    Men with prostate cancer at higher risk of venous thromboembolism.
    Cancer. 2022;128:3585.
    PubMed    
    
    
    September 2022
71. KOWALCHUK RO, Kim H, Harmsen WS, Jeans EB, et al
    Cost effectiveness of treatment strategies for high risk prostate cancer.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34450.
    PubMed     Abstract available
    
    
    
72. LILLARD JW JR, Moses KA, Mahal BA, George DJ, et al
    Racial disparities in Black men with prostate cancer: A literature review.
    Cancer. 2022 Sep 6. doi: 10.1002/cncr.34433.
    PubMed     Abstract available
    
    
    August 2022
73. HILSCHER M, Roder A, Helgstrand JT, Klemann N, et al
    Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
    Cancer. 2022 Aug 17. doi: 10.1002/cncr.34407.
    PubMed     Abstract available
    
    
    July 2022
74. FANG AM, Shumaker LA, Martin KD, Jackson JC, et al
    Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Cancer. 2022 Jul 12. doi: 10.1002/cncr.34355.
    PubMed     Abstract available
    
    
    
75. O'ROURKE K
    Can multiparametric ultrasound be used for prostate cancer?
    Cancer. 2022;128:2399.
    PubMed    
    
    
    June 2022
76. NNATE DA, Ball J
    Current prostate cancer screening and treatment strategies may not support a holistic nationwide program.
    Cancer. 2022 Jun 1. doi: 10.1002/cncr.34337.
    PubMed     Abstract available
    
    
    March 2022
77. MENDES AA, Lu J, Kaur HB, Zheng SL, et al
    Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Cancer. 2022 Mar 25. doi: 10.1002/cncr.34190.
    PubMed     Abstract available
    
    
    
78. O'ROURKE K
    Gut microbiome linked to aggressive prostate cancer.
    Cancer. 2022;128:938.
    PubMed    
    
    
    February 2022
79. MCDONALD AC, Gernand J, Geyer NR, Wu H, et al
    Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
    Cancer. 2022 Feb 23. doi: 10.1002/cncr.34128.
    PubMed     Abstract available
    
    
    January 2022
80. WITTMANN D, Mehta A, Bober SL, Zhu Z, et al
    TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results.
    Cancer. 2022 Jan 5. doi: 10.1002/cncr.34076.
    PubMed     Abstract available
    
    
    December 2021
81. TILBURT JC, Zahrieh D, Pacyna JE, Petereit DG, et al
    Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
    Cancer. 2021 Dec 10. doi: 10.1002/cncr.34062.
    PubMed     Abstract available
    
    
    
82. HAY A
    Stockholm3 tests improve prostate cancer screening.
    Cancer. 2021;127:4328-4329.
    PubMed    
    
    
    November 2021
83. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    PubMed     Abstract available
    
    
    
84. LIM JE, Huang J, Mnnist S, Weinstein SJ, et al
    Hair dye use and prostate cancer risk: A prospective analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.
    Cancer. 2021 Nov 19. doi: 10.1002/cncr.34035.
    PubMed     Abstract available
    
    
    September 2021
85. KIRK PS, Zhu K, Zheng Y, Newcomb LF, et al
    Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
    Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911.
    PubMed     Abstract available
    
    
    August 2021
86. PATEL HD, Koehne EL, Shea SM, Bhanji Y, et al
    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33875.
    PubMed     Abstract available
    
    
    
87. EZENWANKWO EF, Nnaji CA
    Prostate cancer and the added burden of COVID-19 in sub-Saharan Africa: Rethinking regional priorities for responsive and data-driven cancer control programs.
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33887.
    PubMed    
    
    
    
88. GARLAND SN, Savard J, Eisel SL, Wassersug RJ, et al
    A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33850.
    PubMed     Abstract available
    
    
    
89. NIERENGARTEN MB
    Health literacy may determine treatment choice for favorable-risk prostate cancer: Results from a new trial show that men with low health literacy are less likely to choose active surveillance for prostate cancer after genomic testing.
    Cancer. 2021;127:2825-2826.
    PubMed    
    
    
    
90. NECCHI A, Cucchiara V, Grivas P, Bratslavsky G, et al
    Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865.
    PubMed     Abstract available
    
    
    
91. MEISSNER VH, Olze L, Schiele S, Ankerst DP, et al
    Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33836.
    PubMed     Abstract available
    
    
    
92. BERGEROT CD, Williams SB, Klaassen Z
    Fear of cancer recurrence among patients with localized prostate cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33837.
    PubMed    
    
    
    
93. COURTNEY PT, Deka R, Kotha NV, Cherry DR, et al
    Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33824.
    PubMed     Abstract available
    
    
    July 2021
94. SERAPHIN TP, Joko-Fru WY, Hammerl L, Griesel M, et al
    Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33818.
    PubMed     Abstract available
    
    
    
95. GREENBERG SA, Washington SL 3rd
    The state of our understanding of prostate cancer in sub-Saharan Africa.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33815.
    PubMed    
    
    
    
96. FERRARO S, Rossi RS, Biganzoli EM
    Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33811.
    PubMed    
    
    
    
97. KIM DW, Tilki D, D'Amico AV
    Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer and a Gleason score of 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33813.
    PubMed    
    
    
    
98. PRINTZ C
    Prostate cancer in Black men responds better to immunotherapy.
    Cancer. 2021;127:2389.
    PubMed    
    
    
    
99. KIM DW, Chen MH, Wu J, Huland H, et al
    Prostate-specific antigen levels of 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Cancer. 2021;127:2222-2228.
    PubMed     Abstract available
    
    
    
100. PATEL DC, He H, Berry MF, Yang CJ, et al
     Cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible.
     Cancer. 2021;127:2302-2310.
     PubMed     Abstract available
     
     
     June 2021
101. RUDE T, Walter D, Ciprut S, Kelly MD, et al
     Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration.
     Cancer. 2021 Jun 29. doi: 10.1002/cncr.33643.
     PubMed     Abstract available
     
     
     
102. QUINN TP, Sanda MG, Howard DH, Patil D, et al
     Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
     Cancer. 2021 Jun 17. doi: 10.1002/cncr.33518.
     PubMed     Abstract available
     
     
     
103. MCMAHON GC, Leapman MS
     A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk.
     Cancer. 2021 Jun 3. doi: 10.1002/cncr.33619.
     PubMed    
     
     
     
104. HUDNALL MT, Desai AS, Tsai KP, Weiner AB, et al
     It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?
     Cancer. 2021 Jun 3. doi: 10.1002/cncr.33621.
     PubMed     Abstract available
     
     
     
105. HOWARD DH, Quek RGW, Fox KM, Arondekar B, et al
     The value of new drugs for advanced prostate cancer.
     Cancer. 2021 Jun 1. doi: 10.1002/cncr.33662.
     PubMed     Abstract available
     
     
     
106. PARIKH RB, Gallo JJ, Wong YN, Robinson KW, et al
     Long-term depression incidence and associated mortality among African American and White prostate cancer survivors.
     Cancer. 2021 Jun 1. doi: 10.1002/cncr.33656.
     PubMed     Abstract available
     
     
     May 2021
107. HUNT TC, Ambrose JP, Haaland B, Kawamoto K, et al
     Decision fatigue in low-value prostate cancer screening.
     Cancer. 2021 May 27. doi: 10.1002/cncr.33644.
     PubMed     Abstract available
     
     
     
108. COLE AP, Herzog P, Iyer HS, Marchese M, et al
     Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
     Cancer. 2021 May 17. doi: 10.1002/cncr.33564.
     PubMed     Abstract available
     
     
     
109. GEORGE DJ, Halabi S, Heath EI, Sartor AO, et al
     A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
     Cancer. 2021 May 5. doi: 10.1002/cncr.33589.
     PubMed     Abstract available
     
     
     April 2021
110. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
     Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
     Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
     PubMed     Abstract available
     
     
     
111. BAUER JE
     Prostate cancer survivorship, deaths, and health care management.
     Cancer. 2021 Apr 21. doi: 10.1002/cncr.33588.
     PubMed    
     
     
     
112. WEINER AB, Li EV, Desai AS, Press DJ, et al
     Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis.
     Cancer. 2021 Apr 21. doi: 10.1002/cncr.33584.
     PubMed     Abstract available
     
     
     
113. ONDERDONK BE, Dorn PL, Martinez C, Arif F, et al
     A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.
     Cancer. 2021 Apr 21. doi: 10.1002/cncr.33556.
     PubMed     Abstract available
     
     
     
114. BITTERMAN DS, Chen MH, Wu J, Renshaw AA, et al
     Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
     Cancer. 2021 Apr 6. doi: 10.1002/cncr.33543.
     PubMed     Abstract available
     
     
     
115. ALIBHAI SMH, Breunis H, Hansen AR, Gregg R, et al
     Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
     Cancer. 2021 Apr 2. doi: 10.1002/cncr.33523.
     PubMed     Abstract available
     
     
     
116. IYER HS, Gomez SL, Chen JT, Trinh QD, et al
     Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position.
     Cancer. 2021 Apr 2. doi: 10.1002/cncr.33506.
     PubMed     Abstract available
     
     
     February 2021
117. NABI J, Tully KH, Cole AP, Marchese M, et al
     Access denied: The relationship between patient insurance status and access to high-volume hospitals.
     Cancer. 2021;127:577-585.
     PubMed     Abstract available
     
     
     January 2021
118. NGUYEN DD, Trinh QD, Cole AP, Kilbridge KL, et al
     Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
     Cancer. 2021;127:249-256.
     PubMed     Abstract available
     
     
     
119. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
     Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
     Cancer. 2021;127:275-283.
     PubMed     Abstract available
     
     
     June 2020
120. PRINTZ C
     Price transparency still an issue for cancer center costs.
     Cancer. 2020;126:2733.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.